---
title: "G Sachs: BeOne Medicines Ltd.  2Q Sales Slightly Beat Forecasts, Buy Rating Maintained"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296753588.md"
description: "Goldman Sachs maintained a Buy rating on BeOne Medicines, noting its Q2 sales slightly beat forecasts with revenue up 29% YoY to USD1.68 billion, driven by strong Brukinsa performance. Consequently, the firm raised full-year 2026 guidance for revenue and profits, increased EPS forecasts for 2026-2028, and lifted the US stock target price from USD414.46 to USD441.3."
datetime: "2026-08-24T08:01:41.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296753588.md)
  - [en](https://longbridge.com/en/news/296753588.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296753588.md)
generator: "portal-rs"
---

# G Sachs: BeOne Medicines Ltd.  2Q Sales Slightly Beat Forecasts, Buy Rating Maintained

G Sachs released a research report saying that BEONE MEDICINES (06160.HK) -6.200 (-2.719%) Short selling $94.18M; Ratio 28.104% recorded product sales revenue of USD1.68 billion in 2Q, up 29% YoY and slightly above the broker's and market expectations. Core product Brukinsa continued to deliver strong global sales performance, rising 31% YoY to USD1.25 billion, further consolidating its leadership position in the global BTK inhibitor market with a market share of 38%. Its US market sales increased 31% YoY to USD893 million, above the broker's forecast of USD822 million.

In response to the strong 2Q performance, management again raised its full-year 2026 guidance. Total revenue guidance was lifted from USD6.3 billion-USD6.5 billion to USD6.6 billion-USD6.8 billion; GAAP operating profit guidance was raised from USD750 million-USD850 million to USD1 billion-USD1.1 billion; non-GAAP operating profit guidance was increased from USD1.45 billion-USD1.55 billion to USD1.7 billion-USD1.8 billion. G Sachs also raised its 2026-2028 EPS forecasts and increased the US stock TP for BeOne Medicines Ltd. (ONC.US) from USD414.46 to USD441.3, while maintaining the Buy rating. (gc/u)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-08-24 12:25.) (Real-time Streaming US Stocks Quote; Except All OTC quotes are at least 15 minutes delayed.)

### Related Stocks

- [ONC.US](https://longbridge.com/en/quote/ONC.US.md)
- [BGNE.US](https://longbridge.com/en/quote/BGNE.US.md)
- [06160.HK](https://longbridge.com/en/quote/06160.HK.md)
- [688235.CN](https://longbridge.com/en/quote/688235.CN.md)
- [GS.US](https://longbridge.com/en/quote/GS.US.md)
- [W4VR.SG](https://longbridge.com/en/quote/W4VR.SG.md)

## Related News & Research

- [BeOne Medicines Announces Voluntary Agreement with U.S. Government to Expand Access to Innovative Cancer Medicines | ONC Stock News](https://longbridge.com/en/news/297552849.md)
- [BeOne Medicines Grants RSUs to 235 Employees Under Incentive Plan](https://longbridge.com/en/news/298025672.md)
- [CLSA: China Biotech Fundamentals Remain Solid; Top Picks BEONE MEDICINES , INNOVENT BIO  and LEADS BIOLABS-B](https://longbridge.com/en/news/297994035.md)
- [BeOne Medicines to Present at the Morgan Stanley Annual Global Healthcare Conference | ONC Stock News](https://longbridge.com/en/news/297636674.md)
- [Reddit CEO Steve Huffman to speak at Goldman Sachs Communacopia + Technology Conference](https://longbridge.com/en/news/297656621.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**